Raloxifene-d4 (hydrochloride) |
| Catalog No.GC48023 |
Le raloxifène-d4 (chlorhydrate) est le raloxifène marqué au deutérium. Le raloxifène (Kéoxifène) est un modulateur sélectif des récepteurs aux œstrogènes (SERM) dérivé du benzothiophène. Le raloxifène a des effets agonistes des œstrogènes sur les os et les lipides et des effets antagonistes des œstrogènes sur le sein et l'utérus. Le raloxifène est utilisé pour la recherche sur le cancer du sein et l'ostéoporose.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1188263-47-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Raloxifene-d4 is intended for use as an internal standard for the quantification of raloxifene by GC- or LC-MS. Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.1 Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED50 = 0.2 mg/kg).2,1 Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.3
1.Black, L.J., Sato, M., Rowley, E.R., et al.Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsJ. Clin. Invest.93(1)63-69(1994) 2.Wong, C.M., Yung, L.M., Leung, F.P., et al.Raloxifene protects endothelial cell function against oxidative stressBr. J. Pharmac.155(3)326-334(2008) 3.Özmen, B., Kirmaz, C., Aydin, K., et al.Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-α, TGF-ß1 and bone turnover markers in the treatment of postmenopausal osteoporosisEur. Cyto. Netw.18(3)148-153(2007)
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *